Zscaler Inc. (NASDAQ: ZS) beat revenue and earnings estimates for the second quarter of 2020 but the outlook fell below estimates, causing the stock to crash by more than 10% in aftermarket hours on Thursday.
The cloud security company reported a 36% year-over-year increase in total revenue to $101.3 million, beating forecasts of $98.9 million.
GAAP net loss was $29.2 million, or $0.23 per share, compared to $3.6 million, or $0.03 per share, in the prior-year period. Adjusted net income totaled $12 million, or $0.09 per share, surpassing projections of $0.03 per share.
Calculated billings grew 18% to $135.4 million and deferred revenue increased 36% to $280 million compared to last year.
For the third quarter of 2020, the company expects total revenue of $105-107 million and adjusted EPS of approx. $0.01-0.03. This fell short of Wall Street’s estimates of $0.04 per share for the third quarter.
For the full year of 2020, revenue is expected to be $414-417 million and adjusted EPS is expected to be $0.14-0.16. Calculated billings is estimated to range between $512-517 million.
Zscaler has been strengthening its product portfolio to keep pace with industry leaders like Cisco (CSCO) while giving competition to peers. As a result, the company continues to expand its user-base. More and more businesses, including top-tier companies, are adopting Zscaler’s cloud security solutions.
According to Allied Market Research, the global cloud security market is expected to grow to $8.9 billion by 2020, reflecting a CAGR of 23.5% during the period from 2015-2020.
Last month, Zscaler reached an agreement with Broadcom (NASDAQ: AVGO), resulting in the dismissal of all patent lawsuits filed against Zscaler by Symantec, which was acquired by Broadcom. As part of the settlement, Zscaler agreed to pay $15 million to Broadcom.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on